Malignancies in Man After Organ Transplantation

  • L. J. Kinlen
Conference paper


Even before the question could be studied in man, an increased incidence of cancer in organ transplant recipients was implied by the immunosurveillence hypothesis proposed by Thomas (1959) and Burnet (1965). Their predictions have been amply confirmed by observations since then, but in ways that have helped to modify the original theory. These observations have come from follow-up studies of transplant recipients, together with details of malignancies collected from around the world by Penn. The findings, briefly reviewed here, are of both clinical and scientific interest.


Transplant Recipient Transplant Patient Basal Cell Carcinoma Renal Transplant Recipient Primary Liver Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anderson JL, Bieber CP, Fowles RE, Stinson EB (1978) Idiopathic cardiomyopathy, age and suppressor-cell dysfunction as risk determinants of lymphoma after cardiac transplantation. Lancet 2:1174–1177PubMedCrossRefGoogle Scholar
  2. Bencini PL, Montagnino G, DeVecchi A, Crosti C, Tarantino A (1986) Cutaneous lesions in 67 cyclosporin-treated renal transplant recipients. Dermatologica 172:24–30PubMedCrossRefGoogle Scholar
  3. Burnet FM (1965) Somatic mutation and chronic disease. Br Med J:338–342Google Scholar
  4. Calne RY, Rolles K, Thiru S, McMaster P, Craddock GN, Aziz S, White DJG, Evans DB, Dunn DC, Henderson RG, Lewis G (1979) Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 2:1033–1036PubMedCrossRefGoogle Scholar
  5. Cutler SJ, Young JL (1975) (eds) Third national cancer survey: incidence data. NCI Monogr 41Google Scholar
  6. Doll R, Kinlen L (1970) Immunosurveillance and cancer: epidemiological evidence. Br Med J 4:420–422PubMedCrossRefGoogle Scholar
  7. Hoover R, Fraumeni JF Jr (1973) Risk of cancer in renaltransplant recipients. Lancet 2:55–57PubMedCrossRefGoogle Scholar
  8. Hoover R, Fraumeni JF Jr (1982) Personal communication quoted in Kinlen 1982. In: Cancer Surveys 1:4Google Scholar
  9. Kay HE (1983) Immunosuppression and the risk of brain lymphomas. N Engl J Med 308:1099–1100PubMedGoogle Scholar
  10. Kinlen LJ (1982) Immunosuppressive therapy and cancer. Cancer Surveys 1:565–583Google Scholar
  11. Kinlen LJ (1985) Incidence of cancer in rheumatoid athritis and other disorders after immunosuppressive treatment. Am J Med 78 (Suppl 1A): 44–49PubMedCrossRefGoogle Scholar
  12. Kinlen LJ, Sheil AGR, Peto J, Doll R (1979) A collaborative U.K.-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 2: 1461–1466PubMedCrossRefGoogle Scholar
  13. Kinlen LJ, Doll R, Peto J (1983) The incidence of tumors in human transplant recipients. Transplant Proc 15:1039–1042Google Scholar
  14. Kripke ML (1981) Immunologic mechanisms in UV radiation carcinogenesis. Adv Cancer Res 34:69–106PubMedCrossRefGoogle Scholar
  15. Penn I (1979) Host origin of lymphomas in organ transplant recipients. Transplantation 27:214PubMedCrossRefGoogle Scholar
  16. Penn I (1982) The occurrence of cancer in immune deficiencies. Curr Probi Cancer 6:10Google Scholar
  17. Penn I (1988) Transmission of cancer with donor organs. Transplant Proc 20:739–740PubMedGoogle Scholar
  18. Sheil AGR, Flavel S, Disney APS, Mathew TH, Hall BM (1987) Cancer incidence in renal transplant patients treated with azathioprine or cyclosporine. Transpl Proc 19:2214–2216Google Scholar
  19. Smith JL, Wilkinson AH, Hunsicker LG, Tobacman J, Kapelanski DP, Johnson M, Wright FH, Behrendt DM, Corry RJ (1989) Increased frequency of posttrans-plant lymphomas in patients treated with cyclosporin, azathioprine and prednisone. Transplant Proc 21:3199–3200PubMedGoogle Scholar
  20. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW, Hardesty RL, Atchison RW, Jaffe R (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1:583–587PubMedCrossRefGoogle Scholar
  21. Thomas L (1959) Discussion. In: Lawrence HS (ed) Cellular and humoral aspects of the hypersensitive states. Hoeber-Harfer, New York, pp 529–532Google Scholar
  22. Walder BK, Robertson MR, Jeremy D (1971) Skin cancer and immunosuppression. Lancet 2:1282–1283PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • L. J. Kinlen

There are no affiliations available

Personalised recommendations